Furthermore, because post-stroke immunosuppression persists for a period time in AIS recovery, ARG1 inhibition may have a beneficial effect on AIS severity and outcome even administered at a later time point than recanalization agents, such as rTPA. The gene discussed is ARG1; the disease is Stroke.